This model was used to test 1) if the difference between the 2 methods was significant; 2) if the observed differences were significantly different for each alloantibody
; and 3) if the observed differences for any alloantibody
type were different to the combination of the others.
He had one MNS group alloantibody
, anti-S, which can trigger a severe transfusion reaction.
Demonstration of reduced alloantibody
levels with the CryoValve SG can be a key consideration for cardiac surgeons when replacing the pulmonary valve.
After a short incubation, rabbit serum was added as a source of complement, and the cells that had bound the alloantibody
were lysed, making them permeable to the fluorochrome ethidium bromide.
These patients have a high likelihood for developing an alloantibody
following red cell transfusion.
The new additive happened to inactivate one clinically significant antigen, which resulted in missing the alloantibody
present in this patient's blood.
A panreactive autoantibody can mask an existing alloantibody
by making all donor units appear cross-match incompatible.
CLSI guideline, "Detection of HLA-Specific Alloantibody
by Flow Cytometry and Solid Phase Assays; Approved Guideline," describes criteria for optimizing flow cytometry cross matching and the detection of human leukocyte antigen (HLA) alloantibody
by solid phase methods in conventional and multiplex platforms.
Because these recently transfused patients have a chimera of donor and recipient cells, an autologous adsorption may actually remove a clinically significant alloantibody
which may be reacting only with donor cells.
At the FDA's suggestion, the company intends to submit a protocol for a Phase 2 randomized trial for the treatment of autoimmune hemolytic anemia and other forms of hemolytic anemia, including alloantibody
anemia but excluding sickle cell anemia.
CLSI has also published a new document, Detection of HLA-Specific Alloantibody
by Flow Cytometry and Solid Phase Assays; Approved Guideline (I/LA29-A), which describes criteria for optimizing flow cytometry crossmatching and the detection of human leukocyte antigen (HLA) alloantibody
by solid-phase methods in conventional and multiplex platforms.